1. Home
  2. SMTI vs CLLS Comparison

SMTI vs CLLS Comparison

Compare SMTI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sanara MedTech Inc.

SMTI

Sanara MedTech Inc.

HOLD

Current Price

$34.19

Market Cap

313.5M

Sector

Health Care

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

N/A

Current Price

$3.18

Market Cap

394.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SMTI
CLLS
Founded
1982
1999
Country
United States
France
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
313.5M
394.4M
IPO Year
2008
2014

Fundamental Metrics

Financial Performance
Metric
SMTI
CLLS
Price
$34.19
$3.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$34.00
$8.33
AVG Volume (30 Days)
344.1K
15.5K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,586,976.00
N/A
Revenue This Year
$17.31
N/A
Revenue Next Year
$12.48
$0.98
P/E Ratio
N/A
N/A
Revenue Growth
32.47
N/A
52 Week Low
$16.05
$2.35
52 Week High
$35.70
$5.48

Technical Indicators

Market Signals
Indicator
SMTI
CLLS
Relative Strength Index (RSI) 81.05 63.18
Support Level $20.47 $3.12
Resistance Level $34.33 $3.40
Average True Range (ATR) 0.74 0.15
MACD 0.14 0.05
Stochastic Oscillator 97.65 100.00

Price Performance

Historical Comparison
SMTI
CLLS

About SMTI Sanara MedTech Inc.

Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: